AUTOLUS THERAPEUTICS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.39 USD | +7.86% |
|
+10.03% | -31.83% |
| May. 17 | European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading | MT |
| May. 17 | Syncona notes Autolus's first quarter loss widens amid higher costs | AN |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 22.04M | Sales 2025 * | 71.64M | Capitalization | 1.17B |
|---|---|---|---|---|---|
| Net income 2024 * | -216M | Net income 2025 * | -132M | EV / Sales 2024 * | 20.9 x |
| Net cash position 2024 * | 707M | Net cash position 2025 * | 624M | EV / Sales 2025 * | 7.59 x |
| P/E ratio 2024 * |
-4.91
x | P/E ratio 2025 * |
-8.32
x | Employees | 467 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 3.32% |
More Fundamentals
* Assessed data
More news
Latest transcript on Autolus Therapeutics plc
More recommendations
More press releases
| 1 day | +7.86% | ||
| 1 week | +10.03% | ||
| Current month | +19.29% | ||
| 1 month | -9.30% | ||
| 3 months | -35.72% | ||
| 6 months | -1.35% | ||
| Current year | -31.83% |
1 week
3.75
4.84
1 month
3.614.87
Current year
3.617.45
1 year
2.017.45
3 years
1.608.23
5 years
1.6023.52
10 years
1.6053.24
| Managers | Title | Age | Since |
|---|---|---|---|
Martin Pulé
FOU | Founder | 51 | 14-08-31 |
Christian Itin
CEO | Chief Executive Officer | 59 | 14-09-30 |
Robert Dolski
DFI | Director of Finance/CFO | 54 | 23-08-06 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
John Berriman
BRD | Director/Board Member | 76 | 14-07-31 |
William Young
BRD | Director/Board Member | 79 | 21-11-14 |
Cynthia Butitta
BRD | Director/Board Member | 70 | 18-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.05% | 2 M€ | -.--% | ||
| 0.01% | 0 M€ | 0.00% | - | |
| 0.01% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 4.39 | +7.86% | 2,033,189 |
| 24-05-16 | 4.07 | +3.56% | 2,575,944 |
| 24-05-15 | 3.93 | 0.00% | 984,418 |
| 24-05-14 | 3.93 | -2.00% | 1,008,063 |
| 24-05-13 | 4.01 | +0.50% | 1,062,536 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotes
Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells. It has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
4.39
USD
Average target price
10.54
USD
Spread / Average Target
+140.19%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -31.83% | 1.17B | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -14.15% | 21.84B | |
| -1.05% | 21.96B | |
| -5.29% | 19.21B | |
| -38.29% | 17.71B | |
| -4.16% | 18.08B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- AUTL Stock
